[{"orgOrder":0,"company":"Ancilia Bioscience","sponsor":"ARPA-H","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ancilia Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ancilia Bioscience \/ ARPA-H","highestDevelopmentStatusID":"4","companyTruncated":"Ancilia Bioscience \/ ARPA-H"},{"orgOrder":0,"company":"Ancilia Bioscience","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Ancilia Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ancilia Bioscience \/ Safar Partners","highestDevelopmentStatusID":"3","companyTruncated":"Ancilia Bioscience \/ Safar Partners"},{"orgOrder":0,"company":"Ancilia Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Bifidobacterium Longum Subsp. Longum 35624","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Ancilia Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ancilia Bioscience \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ancilia Bioscience \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Ancilia Bioscience

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : Bifidobacterium Longum Subsp. Longum 35624 is a probiotic candidate, which is currently being evaluated in clinical studies for the treatment of Arthritis, Rheumatoid.

                          Product Name : Align Extra Strength Probiotic Supplement

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          December 26, 2025

                          Lead Product(s) : Bifidobacterium Longum Subsp. Longum 35624

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : The funding will enable the company to complete preclinical testing and advance its lead therapeutic candidate through IND submission for a first-in-human clinical trial.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 23, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : ARPA-H

                          Deal Size : $3.0 million

                          Deal Type : Funding

                          blank

                          03

                          BIO Partnering at JPM
                          Not Confirmed
                          BIO Partnering at JPM
                          Not Confirmed

                          Details : The financing supports development of Ancilia’s platform that harnesses CRISPR’s natural function to increase the utility of live bacterial products against viruses.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 17, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Safar Partners

                          Deal Size : $4.2 million

                          Deal Type : Financing

                          blank